Research and Development of Domestic Pharmaceutical Enterprises in 2016

2016 is a year of profound changes in China's pharmaceutical industry. The state has issued far-reaching policies in various links such as drug research and development, registration and declaration, circulation, and terminal payment. For example, it promotes industry reshuffle by promoting consistency evaluation, eliminates backward industrial production capacity, and encourages new drug research and development innovation to improve domestic enterprises. Core competitiveness.

Despite frequent policy panics, judging from the financial statements of 92 listed pharmaceutical companies that have published 2016 annual reports, about two-thirds of pharmaceutical companies have achieved double-digit net profit growth, which is also the result of domestic enterprises' active response to changes in the external environment.

At the same time, many domestic pharmaceutical companies are actively transforming, from raw materials to preparations, from small molecules to biological drugs, from deep domestic to overseas and so on. There is no doubt that such a transformation is driven by technology and capital, and cannot be separated from large-scale R & D investment. Although it is far from comparable to the annual research and development investment of US $10 billion by global pharmaceutical giants (observation of research and development expenses of pharmaceutical giants in 2016: Roche exceeded US $10 billion for the first time), several domestic pharmaceutical companies in the first echelon of research and development have expanded their leading advantages by virtue of their long-term high research and development investment.

In 2016, China Biopharmaceutical (HK $1.599 billion), Hengrui Pharmaceutical (1.184 billion yuan) and Fosun Pharmaceutical (1.106 billion yuan) will invest more than 1 billion yuan in research and development;

In 2016, the pharmaceutical companies whose R & D investment accounted for more than 10% of operating income were Kangyuan Pharmaceutical (12.06), Hengrui Pharmaceutical (10.68) and China Biopharmaceutical (10.10);

The three pharmaceutical companies with the largest increase in R & D investment in 2016 compared with 2015 are Fosun Pharmaceutical (33.23 per cent), Hengrui Pharmaceutical (32.80 per cent) and Lizhu Group (26.37 per cent). In addition, the R & D investment of Renfu Pharmaceutical, Stone Pharmaceutical Group, Kelun Pharmaceutical and China Biopharmaceutical also increased by more than 20%.

Number of R & D personnel of 8 domestic R & D giants in 2016 and the proportion of total employees

In terms of the number of R & D personnel, the companies with more than 1000 R & D teams mainly include Hengrui Pharmaceuticals, Kelun Pharmaceuticals, Renfu Pharmaceuticals and Tianshili. Hengrui is the pharmaceutical company with the largest R & D team, with more than 2000 people, accounting for 17% of the total number of employees in the company. In other words, if Hengrui convenes all employees for a meeting, one in every six people will be a scientist engaged in R & D. Kelun Pharmaceuticals has expanded dramatically in recent years and has more than 1800 R & D personnel.

Capital and manpower are the two main factors of R & D investment, and the above data also generally reflect the overall strength of the first echelon of domestic R & D pharmaceutical enterprises. May these companies be able to produce reassurance drugs in the context of generic drug consistency evaluation, so that patients can benefit.